CEFA
HQL

Closed-End Fund Advisors’s abrdn Life Sciences Investors HQL Stock Holding History

Closed-End Fund Advisors’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$604K Buy
30,171
+3,668
+14% +$64.8K 0.59% 59
2026
Q1 		$431K Sell
26,503
-3,203
-11% -$53.5K 0.44% 76
2025
Q4 		$498K Buy
+29,706
New +$499K 0.29% 87

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return
1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

Closed-End Fund Advisors's HQL Position: Q2 2026 in Review

Closed-End Fund Advisors increased its abrdn Life Sciences Investors (HQL) stake by 14% in Q2 2026, buying an estimated $64.8K and bringing the position to 30,171 shares worth $604K. The position accounts for 0.59% of the portfolio, ranked #59.

Closed-End Fund Advisors first reported a position in HQL in Q4 2025 and has held it in 3 quarters since. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

  • Closed-End Fund Advisors held 30,171 shares of abrdn Life Sciences Investors worth $604K as of Q2 2026.
  • Closed-End Fund Advisors bought 3,668 abrdn Life Sciences Investors shares in Q2 2026, an estimated $64.8K.
  • abrdn Life Sciences Investors made up 0.59% of Closed-End Fund Advisors's portfolio in Q2 2026, its #59 holding.
  • Closed-End Fund Advisors first reported a position in abrdn Life Sciences Investors in Q4 2025 and has held it in 3 quarters since.
  • 83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on Closed-End Fund Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.